New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multip...(ta from a totalof five studies (four Pha...),Health

-- VELCADE Dexamethasone (Vc/D) versus VcAD as Induction Treatment Prior

to Autologous Stem Cell Transplantation (ASCT) in Previously Untreated

Multiple Myeloma: Updated Data from IFM 2005/01 Trial

-- Lead investigator: Jean-Luc Harousseau, M.D., Hospital Hotel-Dieu,

Nantes, France

-- Abstract #8505: Oral presentation session: Saturday, 31 May,

9:00 a.m. CT

-- Total Therapy (TT) for Myeloma: 10 Percent Cure Rate with TT1 Suggested

by >10 Year Continuous Complete Remission (CCR): VELCADE in TT3

Overcomes Poor Risk Associated with T (4;14) and DelTP53 in TT2

-- Lead investigator: Bart Barlogie, M.D., Ph.D., Director, Myeloma

Institute for Research and Therapy, University of Arkansas for

Medical Sciences

-- Abstract #8516: Oral presentation session: Saturday, 31 May,

3:00 p.m. CT

-- Efficacy of Induction with CyBorD in Newly Diagnosed Multiple Myeloma

-- Lead investigator: Craig Reeder, M.D., Assistant Professor of

Medicine - Mayo Clinic College of Medicine

-- Abstract #8517: Oral presentation session: Saturday, 31 May,

3:15 p.m. CT

-- VELCADE, Pegylated-Lyposomal-Doxorubicin and dexamethasone (PAD) as

Induction Therapy Prior to Reduced Intensity ASCT Followed by

Lenalidomide and Prednisone (LP) as Consolidation and Lenalidomide

Alone as Maintenance

-- Lead investigator: Antonio Palumbo, M.D., Chief of the Myeloma Unit;

Department of Hematology, University of Torino

-- Abstract #8518: Oral presentation session: Saturday, 31 May,